HX016-9

HX016-9 is a preclinical bispecific antibody developed by Hanx Biopharmaceuticals. It is designed to simultaneously target programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). By inhibiting both PD-1, an immune checkpoint that suppresses T-cell activity, and VEGF, a key driver of tumor angiogenesis, HX016-9 aims to disrupt tumor immune evasion and blood vessel growth. This dual-target approach offers a novel strategy for treating solid tumors by combining immunotherapy with antiangiogenic effects[6][5][1]. As of May 2025, HX016-9 remains in the preclinical stage with no registered clinical trials or regulatory approvals[2][6].